Opus Bio to License CD22 CAR T Cell Technology to Juno
Summary
“Juno has assembled the requisite platform to advance this exciting product candidate into the next stages of clinical development and potential commercialization,” said Opus Bio CEO, Douglas Lind.Biomark Capital shares the drive and vision of its portfolio companies to collaborate with them in accelerating growth and building successful business ventures.The modified T cells can be infused into the patient or frozen and stored for later infusion.About Opus BioOpus Bio, Inc. is a diversified biologics company focused on the development and commercialization of breakthrough immunotherapy and cellular approaches for the treatment of cancer.The company has established relationships with leading academic research institutions and biopharmaceutical companies with the intention of identifying promising early-stage innovative therapeutic candidates with a vision toward improving patient outcomesAbout Biomark CapitalBiomark Capital is a venture capital and private equity firm comprised of experienced professionals with over 50 years of combined investment experience generating superior returns.Biomark Capital shares the drive and vision of its portfolio companies to collaborate with them in accelerating growth and building successful business ventures.